NCT00827359View on ClinicalTrials.gov

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

January 31, 2018

Study Completion Date

June 30, 2018

Conditions
Renal Cell CarcinomaRenal Cancer
Interventions
DRUG

Everolimus

Tablet form taken orally once a day

Trial Locations (3)

27710

Duke University Medical Center, Durham

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Duke University
Novartis
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Duke University

OTHER

collaborator

Novartis

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER